Clinical Effect of Celeport in the Treatment of Sensorineural Hearing Loss and Tinnitus.

概要

論文の詳細を見る
The therapeutic effect of Celeport® was studied in 35 patients with chronic sensorineural hearing loss. Their ages ranged from 41 to 79 years (average 65.2). The oral dose of Celeport® was 150 mg daily. The severity of hearing loss and of tinnitus was recorded before and the end of treatment.The medication was effective in improving hearing or reducing tinnitus in 51.4% of the patients. In 35.4% of 65 ears hearing improved. The average hearing level, maximum discrimination level in speech articulation test and threshold of interaural time discrimination in directional hearing were improved. In the patients whose hearing was improved subjectively, the average hearing level and threshold of interaural time discrimination were improved significantly (p<0.001 and p<0.05). However, there was no significant difference in maximum discrimination level before and after of the medication. These results indicate that this drug can improve neural function in the brainstem.This drug reduced tinnitus in 40.0% of the 25 patients with hearing loss plus tinnitus. It was interesting that the medication caused no reduction of pure tone type tinnitus. There was a significant difference in efficacy between band noise type tinnitus and pure tone type tinnitus (p=0.0035).A side effect, erosion of the oral mucosa was detected in one patient, who kept the drug in his mouth for several minutes.Celeport® is considered to be useful in the treatment of chronic hearing loss and/or tinnitus due to neural dysfunction in the brainstem.
耳鼻咽喉科臨床学会の論文

Clinical Effect of Celeport in the Treatment of Sensorineural Hearing Loss and Tinnitus.

スポンサーリンク

概要

著者

関連論文

スポンサーリンク